https://orcid.org/0000-0001-9819-0735
Figures & data
Table 1. Patient demographics and clinical characteristics at index date.
Figure 1. Mean direct healthcare costs per patient. Mean total direct healthcare costs per patient, measured over 12 months of follow-up, are shown for each MPN population ([A] MF, [B] PV, and [C] ET): total case, total control, subgroup case that experienced a TE, and subgroup control that experienced a TE. Total direct healthcare costs are divided into mutually exclusive categories (i.e. inpatient, ER visit, OP office visit, other OP services, OP pharmacy). **p < 0.01; ***p < 0.001. ER: emergency room; ET: essential thrombocythemia; MF: myelofibrosis; OP: outpatient; PV: polycythemia vera; TE: thrombotic event.
![Figure 1. Mean direct healthcare costs per patient. Mean total direct healthcare costs per patient, measured over 12 months of follow-up, are shown for each MPN population ([A] MF, [B] PV, and [C] ET): total case, total control, subgroup case that experienced a TE, and subgroup control that experienced a TE. Total direct healthcare costs are divided into mutually exclusive categories (i.e. inpatient, ER visit, OP office visit, other OP services, OP pharmacy). **p < 0.01; ***p < 0.001. ER: emergency room; ET: essential thrombocythemia; MF: myelofibrosis; OP: outpatient; PV: polycythemia vera; TE: thrombotic event.](/cms/asset/ace247e2-9169-475e-8efd-22ec3aa5ceab/ilal_a_2338849_f0001_c.jpg)
Figure 2. Prevalence of short-term and long-term disability leave per MPN subtype. Mean prevalence of short-term and long-term disability leave is shown for each MPN population ([A, D] MF, [B, E] PV, and [C, F] ET): total case, total control, subgroup case that experienced a TE, and subgroup control that experienced a TE. *p < 0.05; ***p < 0.001. ET: essential thrombocythemia; MF: myelofibrosis; MPN: myeloproliferative neoplasm; PV: polycythemia vera; TE: thrombotic event.
![Figure 2. Prevalence of short-term and long-term disability leave per MPN subtype. Mean prevalence of short-term and long-term disability leave is shown for each MPN population ([A, D] MF, [B, E] PV, and [C, F] ET): total case, total control, subgroup case that experienced a TE, and subgroup control that experienced a TE. *p < 0.05; ***p < 0.001. ET: essential thrombocythemia; MF: myelofibrosis; MPN: myeloproliferative neoplasm; PV: polycythemia vera; TE: thrombotic event.](/cms/asset/df8e0c0f-881b-49bb-bf3e-e70a47d60d3b/ilal_a_2338849_f0002_c.jpg)
Figure 3. Cumulative duration of short-term and long-term disability leave per MPN subtype. Mean cumulative duration of short-term and long-term disability leave is shown for each MPN population ([A, D] MF, [B, E] PV, and [C, F] ET): total case, total control, subgroup case that experienced a TE, and subgroup control that experienced a TE. *p < 0.05; ***p < 0.001. ET: essential thrombocythemia; MF: myelofibrosis; MPN: myeloproliferative neoplasm; PV: polycythemia vera; TE: thrombotic event.
![Figure 3. Cumulative duration of short-term and long-term disability leave per MPN subtype. Mean cumulative duration of short-term and long-term disability leave is shown for each MPN population ([A, D] MF, [B, E] PV, and [C, F] ET): total case, total control, subgroup case that experienced a TE, and subgroup control that experienced a TE. *p < 0.05; ***p < 0.001. ET: essential thrombocythemia; MF: myelofibrosis; MPN: myeloproliferative neoplasm; PV: polycythemia vera; TE: thrombotic event.](/cms/asset/49917138-643e-437e-a20e-52af95255f01/ilal_a_2338849_f0003_c.jpg)
Table 2. Indirect costs (2019 US$) due to disability leave.
Data availability statement
The data that support the findings of this study are available from Merative. Restrictions apply to the availability of these data, which were used under license for this study.